FDA Panel Rejects Novartis Drug for Heart Failure Wall Street Journal Novartis said it had presented its best evidence gathered thus far, but it plans to continue with the drug serelaxin because of the "urgent patient need." Drugs for acute heart failure have generally been very disappointing. The vote by the outside ... Novartis Heart Failure Drug Fails to Win FDA Panel Backing FDA Advisory Panel Recommends Against Approval Of Novartis Heart Failure ... |
